Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach.

ABSTRACT:

Introduction

Nemolizumab is a humanized monoclonal antibody targeting interleukin-31 receptor A. It has shown efficacy in treating patients with prurigo nodularis (PN). In this study, we characterized the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of nemolizumab in patients with PN and compared its efficacy with that of another approved treatment, dupilumab, using a model-based meta-analysis (MBMA).

Methods

We updated an existing population PK (PopPK) model developed for patients with atopic dermatitis (AD) by incorporating data from four clinical studies. The updated model validated the PK of nemolizumab in patients with PN, confirming its relevance and precision. Furthermore, we developed a population PD (PopPD) model to characterize treatment response and asse

SUBMITTER: Takechi T 

PROVIDER: S-EPMC12619860 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature